Visualizing Beta Cells in Patients With a History of Gestational Diabetes

NCT03182296 · Unknown status

Last updated 2026-05-28

This clinical trial tests a new imaging method to visualize beta cells in the pancreas of adults who previously had gestational diabetes.

Status Unknown status The sponsor has not confirmed the status recently.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design Non-randomized, open-label (no blinding) basic-science study

Participants 24 people Planned (estimated).

Who can join Ages 18+ · female only Healthy volunteers accepted.

Timeline Started 2016-11 · est. completion 2026-01

Where 1 site · Netherlands

What this study is testing ClinicalTrials.gov NCT03182296 ↗

Description as written by the study sponsor.

In order to evaluate the difference in beta cell mass in women with and without a history of gestational diabetes mellitus (GDM), investigators aim to compare quantitative PET imaging of the pancreas between these groups. Investigators propose to measure uptake of 68Ga-NODAGA-exendin-4 in the pancreatic beta cells of these women as a measure for beta cell mass. Furthermore, investigators aim to compare uptake of the radiolabeled tracer to beta cell function measured by laboratory parameters. These highly relevant data within this at-risk population for type 2 diabetes (T2D) will provide the investigators with more information on the role of beta cell mass in the predisposition for development of T2D leading to better knowledge on the pathophysiology of this disease. This could be of great interest for development of new treatment options.

Treatments tested

68Ga-NODAGA-exendin-4 PET/CT Radiation

68Ga-NODAGA-exendin-4 PET/CT

Main thing measured	Pancreatic uptake of 68Ga-NODAGA-exendin-4
Sponsor	Radboud University Medical Center
Conditions studied	Gestational Diabetes
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03182296 ↗